Month: June 2021

Media Reports Highlight Energy Storage Market TORONTO and ONTARIO, June 30, 2021 (GLOBE NEWSWIRE) — Sparton Resources Inc. (TSXV: SRI) (“Sparton” or the “Company“) reported today on recent media articles related to large scale energy storage systems (“ESS”) and energy storage technology. The Company currently owns, through its subsidiary VanSpar Mining Inc., a 9.8% equity interest in VRB Energy Inc. (“VRB”) a leading manufacturer of vanadium flow batteries for large scale energy storage related to clean renewable electricity generation. (See Sparton News Release dated March 16, 2021). Possible Ban on Lithium Based Large Scale ESS in China As reported on June 25, 2021, by the Chinese Media Group “Caixing” and UK based “Energy Storage Publishing”, “China is on the verge of banning the use of second-life lithium-ion...

NEWTOWN, Pa., June 30, 2021 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that second quarter of fiscal year 2021 financial results will be released after the market closes on Thursday, August 12th. Management will host a conference call at 5:00 p.m. Eastern Time on August 12th to discuss the results of the quarter. Those who would like to participate may dial 877-407-2988 (201-389-0923 for international callers) and provide access code 13721027. A live webcast of the call will also be provided on the Events section of the Company’s investor relations website and can be accessed directly via the following link: https://78449.themediaframe.com/dataconf/productusers/hls/mediaframe/44540/indexl.html....

SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) — Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced the appointment of Surbhi Sarna to its board of directors effective July 1, 2021. Ms. Surbhi’s medical device experience and her focus on development of strategic partnerships will prove valuable as the company advances its innovation pipeline. “As part of our strategic transformation, we are sharpening our focus on efforts to develop the drug discovery and delivery systems of the future. We are delighted that Surbhi Sarna has agreed to join the Progenity Board of Directors to support these efforts,” said Harry Stylli, Ph.D., CEO, Chairman of the Board, and co-founder of Progenity. “Surbhi’s expertise with the development of FDA-approved medical technologies and her strategic insight will be advantageous as...

– Unyvero studies demonstrated potential for therapy adjustment in 42% to 53% of patients with results available 1 to 2 days faster – Acuitas AMR Gene Panel for Isolates (RUO) studies demonstrate potential in infection control and prevention GAITHERSBURG, Md., June 30, 2021 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced prospective clinical data on the Unyvero LRT BAL presented during a webinar held on June 29, 2021, and data presented at the virtual World Microbe Forum, June 20-24, 2021. The webinar titled “One Academic Medical Center’s Experience with the Unyvero Multiplex Platform for Testing Bronchoalveolar Lavage Fluids: Analytical and Clinical Assessment”...

VICTOR, N.Y., June 30, 2021 (GLOBE NEWSWIRE) — Constellation Brands, Inc. (NYSE: STZ and STZ.B), a leading beverage alcohol company, reported today its first quarter fiscal 2022 results. A conference call to discuss the financial results and outlook will be hosted by President and Chief Executive Officer Bill Newlands and Chief Financial Officer Garth Hankinson on Wednesday, June 30, 2021, at 11:30 a.m. (EDT). Visit cbrands.com/investors/events to locate information for joining the conference call, or a live, listen-only webcast of the conference call. ABOUT CONSTELLATION BRANDS At Constellation Brands (NYSE: STZ and STZ.B), our mission is to build brands that people love because we believe sharing a toast, unwinding after a day, celebrating milestones, and helping people connect, are Worth Reaching For. It’s worth our dedication,...

Further Analyses of GALACTIC-HF Supplement Previously Announced Data Regarding Increased Treatment Effect of Omecamtiv Mecarbil in Patients with More Severe Heart Failure SOUTH SAN FRANCISCO, Calif., June 30, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure) were presented at Heart Failure 2021, an International Congress of the European Society of Cardiology, including a prespecified subgroup analysis of the influence of atrial fibrillation or flutter (AFF) on the treatment effect of omecamtiv mecarbil in a Late Breaking Clinical Trial Session. Other analyses were presented in the Clinical Trial Updates Session related to which patients in GALACTIC-HF achieved...

HARTSVILLE, S.C., June 30, 2021 (GLOBE NEWSWIRE) — Sonoco Protective Solutions, a division of global packaging and sustainability leader Sonoco (NYSE: SON), today announced the expansion of its proprietary Sonopost® packaging technology into Europe. Utilizing current manufacturing infrastructure, strategically located to support this growing opportunity, Sonoco Protective Solutions will expand with a new Sonopost manufacturing operation in Sochaczew, Poland this summer. The Sonopost manufacturing platform uses corner posts made from 100% recycled paperboard to provide a more sustainable packaging solution for large appliances, HVAC units and similar products requiring superior unit protection and exceptional stacking capability. After use, the 100% recyclable corner posts can be bailed with existing paper scrap and recycled in...

PRESS RELEASE June 30, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it has dosed the first patient in a Phase 1 clinical trial of SAN711, a novel molecule derived from Saniona’s proprietary ion channel drug discovery engine. SAN711 is a first-in-class positive allosteric modulator of GABA–A α3 receptors and may be applicable in the treatment of rare neuropathic disorders. Data from the trial are expected in the first half of 2022. The Phase 1 clinical trial will be conducted in approximately 80 healthy volunteers. The primary objective of the study is to determine the tolerability and the maximum tolerated dose of SAN711, which will be evaluated through single ascending dose and multiple ascending dose phases of the study. The secondary objective is to measure...